This article is more than 5 years old. Information may no longer be current.

PediaMed will promote Allergan’s Zymar in pediatric market

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FLORENCE, Ky. — Allergan and PediaMed have agreed to co-promote an anti-infective for the treatment of bacterial conjunctivitis, PediaMed announced in a press release.

PediaMed will promote Zymar (gatifloxacin ophthalmic solution 0.3%, Allergan) in the pediatric marketplace, and Allergan will continue to promote the drug to ophthalmologists, optometrists and other eye care professionals, the release indicated.

“Zymar is the leading treatment for bacterial conjunctivitis in the United States ophthalmology market, and we are confident in PediaMed’s ability to replicate the product’s success with pediatric health care providers,” said Julian Gangolli, Allergan’s corporate vice president and president of U.S. pharmaceuticals, in the release.

The Zymar agreement is the second co-promotion arrangement between the two companies. In 2004, the companies agreed to co-promote Tazorac (tazarotene, Allergan) in the U.S. market as well. PediaMed is responsible for the pediatric marketing.